menu
    • menu
    [{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Induced Pluripotent Stem Cell Derived Natural Killer Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nuwacell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Shanghai 6th People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCR100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Shanghai 6th People's Hospital | Beijing Luhe Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NCR100","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital | Beijing Luhe Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Shanghai 6th People's Hospital | Beijing Luhe Hospital"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NCR101","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NCR102","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nuwacell Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NCR300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nuwacell Biotechnologies \/ The First Affiliated Hospital of University of Science and Technology of China","highestDevelopmentStatusID":"6","companyTruncated":"Nuwacell Biotechnologies \/ The First Affiliated Hospital of University of Science and Technology of China"},{"orgOrder":0,"company":"Nuwacell Biotechnologies","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCR300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nuwacell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nuwacell Biotechnologies \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Nuwacell Biotechnologies \/ Beijing Friendship Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Nuwacell Biotechnologies

    Menu

    Nuwacell Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCR102

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

                            Details : NCR102 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Graft vs Host Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 23, 2025

                            Lead Product(s) : NCR102

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCR101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects W...

                            Details : NCR101 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lung Diseases, Interstitial.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : NCR101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCR100

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Shanghai 6th People's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）

                            Details : NCR100 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 18, 2024

                            Lead Product(s) : NCR100

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Shanghai 6th People's Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCR300

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Beijing Friendship Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（...

                            Details : NCR300 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 04, 2024

                            Lead Product(s) : NCR300

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Beijing Friendship Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Induced Pluripotent Stem Cell Derived Natural Killer Cell

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

                            Details : Human Induced Pluripotent Stem Cell Derived Natural Killer Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 07, 2024

                            Lead Product(s) : Human Induced Pluripotent Stem Cell Derived Natural Killer Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCR100

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Shanghai 6th People's Hospital | Beijing Luhe Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects Wi...

                            Details : NCR100 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 22, 2023

                            Lead Product(s) : NCR100

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Shanghai 6th People's Hospital | Beijing Luhe Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed

                            Nuwacell Biotechnologies

                            China arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCR300

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : The First Affiliated Hospital of University of Science and Technology of China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

                            Details : NCR300 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 12, 2022

                            Lead Product(s) : NCR300

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : The First Affiliated Hospital of University of Science and Technology of China

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth